Chronic Myelogenous Leukemia Diangosis and Treatment
leukemia treatment is required;
otherwise, the disease evolves
naturally into three phases:
Chronic phase: during this
phase, leukemia progresses slowly. In the absence
of treatment, this phase lasts in
average four years. The cancer can be completely asymptomatic.
Over 90% of patients are diagnosed in the
Acceleration phase: this corresponds to
an increase in the proportion of
abnormal white blood cells in the
blood and in the bone marrow, which eventually
leads to an abnormal bone marrow functions, causing fever (without infection), bone pain, and a swollen
a proper treatment is not implemented, the disease progresses after several
months towards the acute phase.
Acute or Blast Crisis
phase: chronic or accelerated leukemia becomes acute (or blast). The bone marrow is invaded by the very young
abnormal white blood cells called blasts, and may not function properly. At this phase,
patients tend to experience the following
Excessive sweating (mostly at
Pressure under the lower left ribs
from a swollen spleen
Rash - small pinpoint red marks on
the skin (petechiae).
Chronic Myeloid Leukemia Treatment
With the advancement in medical
myeloid leukemia treatment provides better results in terms of survival and healing. In recent
treatment of chronic myeloid leukemia has experienced some
great advancement, mainly with the use of targeted therapy, a therapy that allows the drugs
acting on the signals responsible for the
uncontrolled growth of cancer cells.
In chronic myeloid leukemia, these drugs
target the diseased cells carrying
the Philadelphia chromosome
and bcr-abl gene. They help to prevent the development
of chronic myeloid leukemia. In fact, these drugs are
usually the first treatment options considered by most oncologists to fight chronic myeloid leukemia. It has been
several years since imatinib (Gleevec
®) has revolutionized the treatment of
Two other molecules are also available
and reinforce the therapeutic properties of the other
medications: Nilotinib (Tasigna ™) and
®). To combat some resistance
and / or intolerance that some patients experience, the
pharmaceutical industry is working to develop new molecules.
It is necessary to undergo chronic myeloid leukemia
treatment as recommended, and
report all serious side effects to the health care provider. Common serious side effects caused my
medications used in chronic myeloid leukemia treatment
Stomach pain or
myeloid leukemia patients need to
be monitored by an
oncologist or a specialist in blood diseases (hematologist)
during and after the treatment. The monitoring can be scheduled on a weekly
basis at first, then every month,
then every 3 months during the first 2 years of treatment, and hopefully every 4 to
fundamental to assess the tolerance of the treatment
and measure its effectiveness. Regular visits also help the
health care provider to perform different blood tests and
regular monitoring of the effectiveness of the treatment
on the bone marrow. This can require bone marrow aspiration
and analysis of chromosomes as well
measuring bcr-abl gene. Controlling drug concentration in the blood may be
necessary to ensure the right
dosage to prevent overdose and its fetal
1. Besa, EC; Buehler, B; Markman, M; Sacher, RA (27 December
2013). Krishnan, K, ed. "Chronic Myelogenous Leukemia". Medscape Reference. WebMD. Retrieved 3 January 2014.
2. Besa, EC; Buehler, B; Markman, M; Sacher, RA (27 December
2013). Krishnan, K, ed. "Chronic Myelogenous Leukemia Clinical Presentation".
Medscape Reference. WebMD. Retrieved 3 January 2014.
3. Provan, D; Gribben, JG (2010). "Chapter 7 Chronic myelogenous
Molecular Hematology (3rd ed.).
Singapore: Wiley-Blackwell. p. 76. ISBN 9781444318548.
4. Kufe DW; Pollack RE; Weichselbau RR et al., eds. (2003).
"Tyrosine Kinase Inhibitors: Targeting Considerations". Holland-Frei
Cancer Medicine (NCBI
bookshelf book) (6th ed.). Hamilton, Ontario: BC Decker. ISBN 1-55009-213-8. Retrieved October 27, 2012
5. Besa, EC;
Buehler, B; Markman, M; Sacher, RA (27 December 2013). Krishnan, K, ed. "Chronic Myelogenous Leukemia". Medscape
Reference. WebMD. Retrieved 3 January 2014.
6. Jabbour, E.; Cortes,
J. E.; Giles, F. J.; O'Brien, S.; Kantarjian, H. M. (2007). "Current and emerging treatment options in
chronic myeloid leukemia". Cancer 109 (11): 2171–2181. doi:10.1002/cncr.22661.
7. Kantarjian H, Cortes J. Chronic myeloid leukemia. In:
Niederhuber JE, Armitage JO, Doroshow JH, et al., eds. Abeloff's Clinical Oncology. 5th ed.
Philadelphia, Pa: Elsevier Churchill Livingstone; 2013:chap 101.
8. National Cancer Institute: PDQ Chronic Myelogenous Leukemia
Treatment. Bethesda, Md: National Cancer Institute. Date last modified: Nov. 18, 2013. Available at:
http://www.cancer.gov/cancertopics/pdq/treatment/CML/HealthProfessional. Accessed: March 23, 2014.
9. Sokal J, Baccarani
M, Russo D, Tura S (1988). "Staging and prognosis in chronic myelogenous leukemia". Semin Hematol 25 (1): 49–61. PMID 3279515.
10. Chronic myeloid leukaemia (CML) statistics".
Cancer Research UK.